Akari Therapeutics downgraded by Maxim Group
$AKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group downgraded Akari Therapeutics from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2026 | Buy → Hold | Maxim Group | |
| 1/5/2026 | $1.00 | Buy | Ladenburg Thalmann |
| 7/18/2025 | $5.00 | Buy | Maxim Group |
CEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the "What This Means" video here TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor "What This Means" interview focused on the Company's recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. During the interview, Mr. Gaslightwala highlighted the significance of Akari's first ASCO abst
TAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $5.5 million in gross proceeds. With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial. "This financing reflects deep conviction from our long-term strategic investors and positions Akari to build on our
Live webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here TAMPA, Fla. and LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026. Management will discuss the Company's differentiated ADC pipeline, including progress across i
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
D - Akari Therapeutics Plc (0001541157) (Filer)
PRE 14A - Akari Therapeutics Plc (0001541157) (Filer)
8-K - Akari Therapeutics Plc (0001541157) (Filer)
Maxim Group downgraded Akari Therapeutics from Buy to Hold
Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00
Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00
TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core and the Lurie Family Imaging Center at Dana-Farber Cancer Institute, to its Scientific Advisory Board. "Dr. Gokhale's expertise in experimental therapeutics, RNA biology and translational oncology comes at a pivotal time as we advance AKTX-101 toward the clinic," commented Abizer Gaslightwala, President and CEO of Akari Therapeutics. "His proven track record to develop novel t
TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncology payloads, today announced the appointment of Olga Anczukow, Ph.D. to its Scientific Advisory Board (SAB). Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics commented, "Dr. Anczukow is a leading authority in RNA splicing and cancer biology, an area of growing importance for the development of next-generation therapeutics. Her scientific rigor, translational mindset, and experience advancing RNA-focused discoveries toward clinical relevance make her an outstandin
BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of its Scientific Advisory Board (SAB) and inaugural appointment of Dr. Sara Hurvitz. "The formation of our SAB marks an important step in advancing Akari's scientific and clinical strategy, and we are honored to welcome Dr. Sara Hurvitz as its inaugural member," commented Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "In addition to her wealth of knowledge around ADCs, Dr. Hurvitz brings exceptional clinical expertise in the management of can
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D - Akari Therapeutics Plc (0001541157) (Subject)
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be
Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen